Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Kidney Diseases | 9 | 2011 | 55 | 1.630 |
Why?
|
Hypertension | 13 | 2022 | 524 | 1.510 |
Why?
|
Blood Pressure | 8 | 2021 | 310 | 1.360 |
Why?
|
Kidney Failure, Chronic | 10 | 2012 | 151 | 1.080 |
Why?
|
Humans | 72 | 2024 | 18430 | 0.910 |
Why?
|
Transgender Persons | 5 | 2023 | 38 | 0.900 |
Why?
|
Medication Adherence | 6 | 2022 | 267 | 0.900 |
Why?
|
Antihypertensive Agents | 4 | 2021 | 172 | 0.900 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2016 | 182 | 0.840 |
Why?
|
Male | 57 | 2024 | 10440 | 0.840 |
Why?
|
Middle Aged | 48 | 2022 | 8284 | 0.800 |
Why?
|
Albuminuria | 7 | 2011 | 41 | 0.800 |
Why?
|
Renal Insufficiency, Chronic | 5 | 2015 | 180 | 0.760 |
Why?
|
Coronary Disease | 6 | 2016 | 185 | 0.760 |
Why?
|
Societies, Medical | 1 | 2020 | 74 | 0.720 |
Why?
|
Female | 55 | 2024 | 13136 | 0.710 |
Why?
|
Aged | 34 | 2021 | 6417 | 0.630 |
Why?
|
Delivery of Health Care, Integrated | 2 | 2021 | 567 | 0.600 |
Why?
|
Diabetes Mellitus, Type 2 | 4 | 2013 | 760 | 0.600 |
Why?
|
Cardiology | 1 | 2017 | 30 | 0.590 |
Why?
|
American Heart Association | 1 | 2017 | 50 | 0.590 |
Why?
|
United States | 30 | 2017 | 4164 | 0.570 |
Why?
|
Creatinine | 5 | 2010 | 65 | 0.560 |
Why?
|
Adult | 33 | 2022 | 7910 | 0.560 |
Why?
|
Patient Compliance | 2 | 2016 | 318 | 0.550 |
Why?
|
Smoking | 5 | 2014 | 494 | 0.550 |
Why?
|
Health Knowledge, Attitudes, Practice | 4 | 2021 | 392 | 0.530 |
Why?
|
Practice Guidelines as Topic | 2 | 2017 | 333 | 0.530 |
Why?
|
Glomerular Filtration Rate | 8 | 2012 | 157 | 0.510 |
Why?
|
Arabs | 1 | 2014 | 2 | 0.490 |
Why?
|
Tobacco Products | 1 | 2014 | 17 | 0.480 |
Why?
|
Diabetic Nephropathies | 2 | 2011 | 28 | 0.470 |
Why?
|
Heart Failure | 5 | 2022 | 398 | 0.460 |
Why?
|
Adrenal Hyperplasia, Congenital | 2 | 2024 | 6 | 0.460 |
Why?
|
Risk Factors | 24 | 2020 | 3449 | 0.430 |
Why?
|
Cystatin C | 2 | 2009 | 15 | 0.420 |
Why?
|
Atherosclerosis | 2 | 2010 | 51 | 0.420 |
Why?
|
Cardiovascular Diseases | 8 | 2016 | 630 | 0.410 |
Why?
|
Health Behavior | 1 | 2014 | 374 | 0.400 |
Why?
|
Silicon Dioxide | 1 | 2011 | 3 | 0.400 |
Why?
|
Stroke | 6 | 2020 | 311 | 0.400 |
Why?
|
Nutrition Surveys | 11 | 2009 | 63 | 0.400 |
Why?
|
Occupational Diseases | 1 | 2011 | 42 | 0.390 |
Why?
|
Cohort Studies | 17 | 2022 | 2672 | 0.390 |
Why?
|
Occupational Exposure | 1 | 2011 | 67 | 0.380 |
Why?
|
Hypotension, Orthostatic | 1 | 2010 | 1 | 0.380 |
Why?
|
Retrospective Studies | 13 | 2024 | 2550 | 0.370 |
Why?
|
Body Mass Index | 5 | 2024 | 974 | 0.370 |
Why?
|
Aged, 80 and over | 13 | 2021 | 2003 | 0.360 |
Why?
|
Electronic Health Records | 5 | 2020 | 747 | 0.310 |
Why?
|
Peripheral Vascular Diseases | 1 | 2007 | 7 | 0.310 |
Why?
|
Hospitalization | 4 | 2020 | 847 | 0.300 |
Why?
|
Models, Statistical | 1 | 2009 | 185 | 0.300 |
Why?
|
Risk Assessment | 8 | 2020 | 1143 | 0.300 |
Why?
|
Anticholesteremic Agents | 2 | 2014 | 15 | 0.300 |
Why?
|
African Continental Ancestry Group | 2 | 2010 | 166 | 0.290 |
Why?
|
Cognition | 1 | 2007 | 82 | 0.290 |
Why?
|
Follow-Up Studies | 14 | 2022 | 1269 | 0.270 |
Why?
|
African Americans | 5 | 2021 | 490 | 0.260 |
Why?
|
Cardiovascular Agents | 2 | 2016 | 25 | 0.250 |
Why?
|
Food Contamination | 1 | 2005 | 3 | 0.250 |
Why?
|
Fishes | 1 | 2005 | 10 | 0.250 |
Why?
|
Mercury | 1 | 2005 | 4 | 0.250 |
Why?
|
Transsexualism | 2 | 2023 | 10 | 0.240 |
Why?
|
Chronic Disease | 6 | 2011 | 468 | 0.240 |
Why?
|
Kidney | 2 | 2007 | 54 | 0.240 |
Why?
|
Reminder Systems | 2 | 2016 | 94 | 0.240 |
Why?
|
Body Height | 1 | 2024 | 62 | 0.240 |
Why?
|
Kidney Calculi | 1 | 2004 | 6 | 0.240 |
Why?
|
Indians, North American | 3 | 2009 | 50 | 0.240 |
Why?
|
Renal Insufficiency | 1 | 2004 | 13 | 0.240 |
Why?
|
Cross-Sectional Studies | 9 | 2020 | 1360 | 0.240 |
Why?
|
Myocardial Infarction | 2 | 2016 | 249 | 0.230 |
Why?
|
Young Adult | 7 | 2024 | 2518 | 0.220 |
Why?
|
Incidence | 10 | 2020 | 1314 | 0.220 |
Why?
|
Adolescent | 8 | 2024 | 3798 | 0.220 |
Why?
|
Life Style | 2 | 2010 | 342 | 0.210 |
Why?
|
Androgen-Insensitivity Syndrome | 1 | 2022 | 3 | 0.210 |
Why?
|
Disease Progression | 3 | 2013 | 271 | 0.210 |
Why?
|
Sexual and Gender Minorities | 1 | 2023 | 27 | 0.210 |
Why?
|
Self-Injurious Behavior | 1 | 2023 | 44 | 0.210 |
Why?
|
Coronary Artery Disease | 2 | 2014 | 133 | 0.200 |
Why?
|
Social Values | 1 | 2021 | 16 | 0.200 |
Why?
|
Medicare | 3 | 2014 | 214 | 0.200 |
Why?
|
Epidemiologic Studies | 2 | 2020 | 32 | 0.190 |
Why?
|
Databases, Factual | 4 | 2016 | 327 | 0.190 |
Why?
|
Racism | 1 | 2021 | 22 | 0.190 |
Why?
|
Gender Identity | 4 | 2023 | 36 | 0.190 |
Why?
|
Factor Xa Inhibitors | 1 | 2020 | 10 | 0.190 |
Why?
|
Treatment Outcome | 4 | 2020 | 1296 | 0.190 |
Why?
|
European Continental Ancestry Group | 5 | 2020 | 554 | 0.190 |
Why?
|
Health Status Indicators | 1 | 2020 | 71 | 0.180 |
Why?
|
Attitude to Health | 1 | 2021 | 177 | 0.180 |
Why?
|
Health Care Costs | 2 | 2013 | 251 | 0.180 |
Why?
|
Office Visits | 1 | 2021 | 86 | 0.180 |
Why?
|
Primary Prevention | 1 | 2020 | 79 | 0.180 |
Why?
|
Pilot Projects | 1 | 2021 | 237 | 0.180 |
Why?
|
Population Surveillance | 3 | 2012 | 271 | 0.170 |
Why?
|
Prevalence | 6 | 2023 | 911 | 0.170 |
Why?
|
Child | 6 | 2024 | 2571 | 0.170 |
Why?
|
Decision Support Techniques | 1 | 2020 | 95 | 0.170 |
Why?
|
Mental Disorders | 1 | 2023 | 295 | 0.170 |
Why?
|
Case-Control Studies | 3 | 2011 | 1173 | 0.170 |
Why?
|
Glycated Hemoglobin A | 1 | 2021 | 233 | 0.170 |
Why?
|
Cholesterol, LDL | 2 | 2016 | 125 | 0.170 |
Why?
|
Prospective Studies | 8 | 2020 | 1314 | 0.170 |
Why?
|
Suicide, Attempted | 1 | 2020 | 98 | 0.170 |
Why?
|
Substance-Related Disorders | 1 | 2004 | 439 | 0.170 |
Why?
|
Genetic Linkage | 2 | 2009 | 8 | 0.160 |
Why?
|
Obesity, Morbid | 1 | 2020 | 120 | 0.160 |
Why?
|
Atrial Fibrillation | 1 | 2020 | 167 | 0.160 |
Why?
|
Diabetes Mellitus | 4 | 2012 | 530 | 0.160 |
Why?
|
Sex Factors | 5 | 2020 | 661 | 0.160 |
Why?
|
North Carolina | 3 | 2010 | 34 | 0.160 |
Why?
|
Proportional Hazards Models | 9 | 2020 | 743 | 0.160 |
Why?
|
Medical Records | 1 | 2018 | 106 | 0.150 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2016 | 131 | 0.140 |
Why?
|
Risk | 4 | 2010 | 552 | 0.140 |
Why?
|
Severity of Illness Index | 2 | 2016 | 476 | 0.140 |
Why?
|
Medical Record Linkage | 2 | 2016 | 44 | 0.140 |
Why?
|
Social Class | 2 | 2008 | 125 | 0.130 |
Why?
|
Monitoring, Physiologic | 1 | 2016 | 41 | 0.130 |
Why?
|
Drug Costs | 1 | 2016 | 40 | 0.130 |
Why?
|
Drug Administration Schedule | 1 | 2016 | 100 | 0.130 |
Why?
|
HIV Infections | 1 | 2022 | 695 | 0.130 |
Why?
|
Age Factors | 5 | 2020 | 965 | 0.130 |
Why?
|
Needs Assessment | 1 | 2016 | 69 | 0.130 |
Why?
|
Hemoglobins | 2 | 2012 | 39 | 0.120 |
Why?
|
Middle East | 1 | 2014 | 2 | 0.120 |
Why?
|
Health Priorities | 1 | 2014 | 28 | 0.120 |
Why?
|
Smoking Prevention | 1 | 2014 | 55 | 0.120 |
Why?
|
Withholding Treatment | 1 | 2014 | 26 | 0.120 |
Why?
|
Patient Education as Topic | 1 | 2016 | 214 | 0.120 |
Why?
|
Outcome and Process Assessment (Health Care) | 2 | 2012 | 110 | 0.120 |
Why?
|
Coronary Angiography | 1 | 2013 | 22 | 0.110 |
Why?
|
Fee-for-Service Plans | 1 | 2013 | 28 | 0.110 |
Why?
|
Percutaneous Coronary Intervention | 1 | 2013 | 22 | 0.110 |
Why?
|
Medicare Part C | 1 | 2013 | 22 | 0.110 |
Why?
|
Coronary Artery Bypass | 1 | 2013 | 26 | 0.110 |
Why?
|
C-Reactive Protein | 3 | 2009 | 58 | 0.110 |
Why?
|
Data Collection | 2 | 2012 | 275 | 0.110 |
Why?
|
Cost of Illness | 1 | 2013 | 100 | 0.110 |
Why?
|
Biomarkers | 3 | 2016 | 308 | 0.110 |
Why?
|
Research Report | 1 | 2012 | 22 | 0.110 |
Why?
|
Smoking Cessation | 1 | 2014 | 199 | 0.110 |
Why?
|
Benchmarking | 1 | 2012 | 45 | 0.100 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 2 | 2016 | 90 | 0.100 |
Why?
|
Anemia | 1 | 2012 | 32 | 0.100 |
Why?
|
Quantitative Trait Loci | 2 | 2009 | 38 | 0.100 |
Why?
|
Proteinuria | 1 | 2012 | 26 | 0.100 |
Why?
|
Prognosis | 5 | 2014 | 624 | 0.100 |
Why?
|
Physicians, Primary Care | 1 | 2012 | 74 | 0.100 |
Why?
|
Time Factors | 3 | 2020 | 1136 | 0.100 |
Why?
|
Qualitative Research | 1 | 2012 | 272 | 0.100 |
Why?
|
Cholesterol, HDL | 1 | 2011 | 80 | 0.100 |
Why?
|
Quality Indicators, Health Care | 1 | 2012 | 197 | 0.090 |
Why?
|
Quality Improvement | 1 | 2012 | 207 | 0.090 |
Why?
|
Rural Population | 1 | 2010 | 52 | 0.090 |
Why?
|
Perception | 1 | 2010 | 59 | 0.090 |
Why?
|
Diet | 2 | 2002 | 371 | 0.090 |
Why?
|
American Native Continental Ancestry Group | 1 | 2009 | 2 | 0.080 |
Why?
|
Kidney Function Tests | 1 | 2009 | 22 | 0.080 |
Why?
|
Documentation | 1 | 2009 | 45 | 0.080 |
Why?
|
Quality of Life | 2 | 2020 | 529 | 0.080 |
Why?
|
Carbonated Beverages | 1 | 2008 | 14 | 0.080 |
Why?
|
Social Conditions | 1 | 2008 | 2 | 0.080 |
Why?
|
Obesity | 4 | 2009 | 855 | 0.080 |
Why?
|
Logistic Models | 3 | 2008 | 962 | 0.080 |
Why?
|
Residence Characteristics | 2 | 2008 | 256 | 0.080 |
Why?
|
Socioeconomic Factors | 4 | 2014 | 673 | 0.070 |
Why?
|
Metabolic Syndrome | 1 | 2008 | 80 | 0.070 |
Why?
|
Health Promotion | 1 | 2010 | 294 | 0.070 |
Why?
|
Algorithms | 1 | 2008 | 241 | 0.070 |
Why?
|
Models, Biological | 1 | 2007 | 32 | 0.070 |
Why?
|
Medicaid | 1 | 2008 | 211 | 0.070 |
Why?
|
Health Status Disparities | 2 | 2021 | 153 | 0.070 |
Why?
|
Longitudinal Studies | 2 | 2008 | 724 | 0.060 |
Why?
|
Managed Care Programs | 3 | 2012 | 347 | 0.060 |
Why?
|
Anthropometry | 1 | 2024 | 67 | 0.060 |
Why?
|
Infant | 2 | 2024 | 1245 | 0.060 |
Why?
|
Animals | 1 | 2005 | 261 | 0.060 |
Why?
|
Health Status | 2 | 2022 | 328 | 0.060 |
Why?
|
Child, Preschool | 2 | 2024 | 1478 | 0.060 |
Why?
|
Body Weight | 1 | 2024 | 223 | 0.060 |
Why?
|
Lead Poisoning | 1 | 2003 | 3 | 0.060 |
Why?
|
Hypertension, Renal | 1 | 2003 | 4 | 0.060 |
Why?
|
Sexual Development | 1 | 2022 | 4 | 0.050 |
Why?
|
RNA | 1 | 2022 | 12 | 0.050 |
Why?
|
Sodium Chloride, Dietary | 1 | 2002 | 9 | 0.050 |
Why?
|
Fruit | 1 | 2002 | 79 | 0.050 |
Why?
|
Vegetables | 1 | 2002 | 87 | 0.050 |
Why?
|
Folic Acid | 1 | 2002 | 35 | 0.050 |
Why?
|
CD4 Lymphocyte Count | 1 | 2022 | 178 | 0.050 |
Why?
|
Writing | 1 | 2021 | 12 | 0.050 |
Why?
|
Intention to Treat Analysis | 1 | 2021 | 23 | 0.050 |
Why?
|
Single-Blind Method | 1 | 2021 | 47 | 0.050 |
Why?
|
Potassium, Dietary | 1 | 2001 | 1 | 0.050 |
Why?
|
Professional-Patient Relations | 1 | 2021 | 48 | 0.050 |
Why?
|
Mental Health | 1 | 2023 | 168 | 0.050 |
Why?
|
Mass Screening | 1 | 2007 | 690 | 0.050 |
Why?
|
Colorado | 1 | 2021 | 211 | 0.050 |
Why?
|
Illinois | 1 | 2020 | 8 | 0.050 |
Why?
|
Intracranial Hemorrhages | 1 | 2020 | 16 | 0.050 |
Why?
|
Embolism | 1 | 2020 | 6 | 0.050 |
Why?
|
Confidence Intervals | 2 | 2011 | 253 | 0.050 |
Why?
|
Safety | 1 | 2020 | 45 | 0.050 |
Why?
|
Demography | 1 | 2020 | 108 | 0.050 |
Why?
|
Self Report | 1 | 2022 | 256 | 0.040 |
Why?
|
Alcohol Drinking | 1 | 2003 | 375 | 0.040 |
Why?
|
Sex Distribution | 3 | 2009 | 198 | 0.040 |
Why?
|
Sodium, Dietary | 1 | 1999 | 9 | 0.040 |
Why?
|
Lipoproteins | 1 | 1999 | 14 | 0.040 |
Why?
|
Predictive Value of Tests | 1 | 2020 | 365 | 0.040 |
Why?
|
Healthcare Disparities | 1 | 2021 | 211 | 0.040 |
Why?
|
Suicidal Ideation | 1 | 2020 | 100 | 0.040 |
Why?
|
Anxiety | 1 | 2020 | 156 | 0.040 |
Why?
|
Tobacco Smoke Pollution | 1 | 1999 | 34 | 0.040 |
Why?
|
Mortality | 1 | 1999 | 123 | 0.040 |
Why?
|
Hispanic Americans | 1 | 2020 | 428 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 1999 | 342 | 0.040 |
Why?
|
Reference Values | 2 | 2009 | 93 | 0.040 |
Why?
|
Non-ST Elevated Myocardial Infarction | 1 | 2016 | 8 | 0.040 |
Why?
|
Fibrinogen | 2 | 2009 | 13 | 0.030 |
Why?
|
Homocysteine | 2 | 2009 | 13 | 0.030 |
Why?
|
Lipoproteins, LDL | 1 | 2016 | 15 | 0.030 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 1 | 2016 | 10 | 0.030 |
Why?
|
Models, Economic | 1 | 2016 | 22 | 0.030 |
Why?
|
Health Resources | 1 | 2016 | 38 | 0.030 |
Why?
|
Diabetes Complications | 2 | 2010 | 119 | 0.030 |
Why?
|
Depression | 1 | 2020 | 518 | 0.030 |
Why?
|
Cotinine | 2 | 2007 | 7 | 0.030 |
Why?
|
Nutrition Assessment | 2 | 2007 | 27 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 1 | 2015 | 131 | 0.030 |
Why?
|
Cost-Benefit Analysis | 1 | 2016 | 270 | 0.030 |
Why?
|
Propensity Score | 1 | 2015 | 94 | 0.030 |
Why?
|
Comparative Effectiveness Research | 1 | 2015 | 77 | 0.030 |
Why?
|
Lipids | 1 | 2014 | 78 | 0.030 |
Why?
|
Drug Therapy, Combination | 1 | 2014 | 119 | 0.030 |
Why?
|
Capitation Fee | 1 | 2013 | 12 | 0.030 |
Why?
|
Telephone | 1 | 2014 | 179 | 0.030 |
Why?
|
Geography | 1 | 2013 | 41 | 0.030 |
Why?
|
Reimbursement, Incentive | 1 | 2013 | 31 | 0.030 |
Why?
|
Health Surveys | 2 | 2007 | 269 | 0.030 |
Why?
|
User-Computer Interface | 1 | 2012 | 28 | 0.030 |
Why?
|
Health Maintenance Organizations | 1 | 2014 | 479 | 0.030 |
Why?
|
Age of Onset | 1 | 2012 | 82 | 0.030 |
Why?
|
Morbidity | 1 | 2011 | 62 | 0.020 |
Why?
|
Disease Management | 1 | 2012 | 143 | 0.020 |
Why?
|
Oregon | 1 | 2011 | 222 | 0.020 |
Why?
|
Decision Making | 1 | 2012 | 204 | 0.020 |
Why?
|
Energy Intake | 2 | 2002 | 103 | 0.020 |
Why?
|
Interviews as Topic | 1 | 2011 | 327 | 0.020 |
Why?
|
Registries | 1 | 2012 | 490 | 0.020 |
Why?
|
Patient Selection | 1 | 2011 | 198 | 0.020 |
Why?
|
Georgia | 1 | 2009 | 25 | 0.020 |
Why?
|
Focus Groups | 1 | 2010 | 154 | 0.020 |
Why?
|
Health Education | 1 | 2010 | 115 | 0.020 |
Why?
|
Chromosomes, Human, Pair 18 | 1 | 2009 | 1 | 0.020 |
Why?
|
North Dakota | 1 | 2009 | 1 | 0.020 |
Why?
|
South Dakota | 1 | 2009 | 1 | 0.020 |
Why?
|
Oklahoma | 1 | 2009 | 2 | 0.020 |
Why?
|
Chromosomes, Human, Pair 7 | 1 | 2009 | 3 | 0.020 |
Why?
|
Chromosomes, Human, Pair 10 | 1 | 2009 | 3 | 0.020 |
Why?
|
Arizona | 1 | 2009 | 6 | 0.020 |
Why?
|
Hyperuricemia | 1 | 2009 | 2 | 0.020 |
Why?
|
Models, Genetic | 1 | 2009 | 24 | 0.020 |
Why?
|
Phosphorus | 1 | 2009 | 6 | 0.020 |
Why?
|
National Heart, Lung, and Blood Institute (U.S.) | 1 | 2008 | 19 | 0.020 |
Why?
|
Chromosomes, Human, Pair 2 | 1 | 2008 | 1 | 0.020 |
Why?
|
Chromosomes, Human, Pair 12 | 1 | 2008 | 2 | 0.020 |
Why?
|
Chromosomes, Human, Pair 1 | 1 | 2008 | 3 | 0.020 |
Why?
|
Chromosomes, Human, Pair 9 | 1 | 2008 | 7 | 0.020 |
Why?
|
Quantitative Trait, Heritable | 1 | 2008 | 8 | 0.020 |
Why?
|
Chromosome Mapping | 1 | 2008 | 23 | 0.020 |
Why?
|
Defibrillators, Implantable | 1 | 2008 | 32 | 0.020 |
Why?
|
Family Health | 1 | 2008 | 49 | 0.020 |
Why?
|
Research | 1 | 2008 | 73 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2008 | 102 | 0.020 |
Why?
|
Bayes Theorem | 1 | 2008 | 69 | 0.020 |
Why?
|
Phenotype | 1 | 2008 | 148 | 0.020 |
Why?
|
Warfarin | 1 | 2008 | 73 | 0.020 |
Why?
|
Community Health Services | 1 | 2008 | 86 | 0.020 |
Why?
|
Surveys and Questionnaires | 2 | 2002 | 1389 | 0.020 |
Why?
|
Heart Diseases | 1 | 2008 | 77 | 0.020 |
Why?
|
Comorbidity | 1 | 2009 | 619 | 0.020 |
Why?
|
Health Services Accessibility | 1 | 2010 | 320 | 0.020 |
Why?
|
Insulin Resistance | 1 | 2008 | 129 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2007 | 321 | 0.020 |
Why?
|
Primary Health Care | 1 | 2012 | 848 | 0.020 |
Why?
|
Quality of Health Care | 1 | 2008 | 347 | 0.020 |
Why?
|
Aging | 1 | 2007 | 165 | 0.020 |
Why?
|
Hyperhomocysteinemia | 1 | 2003 | 5 | 0.010 |
Why?
|
Inflammation | 1 | 2003 | 63 | 0.010 |
Why?
|
Systole | 1 | 2002 | 22 | 0.010 |
Why?
|
Software | 1 | 2002 | 21 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2002 | 51 | 0.010 |
Why?
|
Mental Recall | 1 | 2002 | 31 | 0.010 |
Why?
|
Myocardial Ischemia | 1 | 2002 | 24 | 0.010 |
Why?
|
Cholesterol | 1 | 2002 | 112 | 0.010 |
Why?
|
Dietary Fats | 1 | 2002 | 92 | 0.010 |
Why?
|
Linear Models | 1 | 2002 | 243 | 0.010 |
Why?
|
Diet Surveys | 1 | 2001 | 58 | 0.010 |
Why?
|
Death Certificates | 1 | 2001 | 19 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2002 | 399 | 0.010 |
Why?
|
Odds Ratio | 1 | 2003 | 701 | 0.010 |
Why?
|
Heart Valve Diseases | 1 | 2001 | 20 | 0.010 |
Why?
|
Educational Status | 1 | 2001 | 205 | 0.010 |
Why?
|
Continental Population Groups | 1 | 2002 | 315 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2001 | 598 | 0.010 |
Why?
|
Analysis of Variance | 1 | 1999 | 167 | 0.010 |
Why?
|
Survival Analysis | 1 | 1999 | 226 | 0.010 |
Why?
|
Cause of Death | 1 | 1999 | 185 | 0.010 |
Why?
|
Environmental Exposure | 1 | 1999 | 115 | 0.010 |
Why?
|
Exercise | 1 | 2001 | 495 | 0.010 |
Why?
|